Back to Results

Virpax Pharmaceuticals Inc (VRPX)

Virpax Pharmaceuticals Inc. is a healthcare company listed on OTC Markets under the ticker VRPX. The company is described as a preclinical-stage pharmaceutical developer focused on drug-delivery systems and drug-releasing technologies for non-opioid and non-addictive pain management, with an emphasis on central nervous system disorders. Its pipeline includes Epoladerm, a topical spray film technology for osteoarthritis pain; Probudur, an injectable liposomal gel candidate for postoperative pain; and Envelta, a nanotechnology-based intranasal spray designed to deliver a metabolically labile peptide into the brain. Additional preclinical programs include AnQlar, an antiviral barrier intended to help reduce the risk or intensity of certain viral infections, and NobrXiol, an investigational nasal formulation aimed at enhancing cannabidiol transport to the brain. Virpax Pharmaceuticals was founded in 2016 and is headquartered in Berwyn, Pennsylvania.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap
OTC-VRPX
Not available
Not available
Not available
Good
0.0%
November 13, 2026
0.001 K
Valuation • Fair Value

Virpax Pharmaceuticals Inc (OTC-VRPX) Fair Value by Valuation Model

No usable valuation estimate is currently available for Virpax Pharmaceuticals Inc (OTC-VRPX); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Virpax Pharmaceuticals Inc (OTC-VRPX). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Virpax Pharmaceuticals Inc (OTC-VRPX)

Review the profitability and growth indicators currently supported by the latest data.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Virpax Pharmaceuticals Inc (OTC-VRPX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Virpax Pharmaceuticals Inc (OTC-VRPX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Virpax Pharmaceuticals Inc (OTC-VRPX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Virpax Pharmaceuticals Inc (OTC-VRPX)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

56

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Virpax Pharmaceuticals Inc (OTC-VRPX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Virpax Pharmaceuticals Inc (OTC-VRPX) Stock Forecast & Technical Outlook

Review Virpax Pharmaceuticals Inc (OTC-VRPX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Virpax Pharmaceuticals Inc (OTC-VRPX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Virpax Pharmaceuticals Inc (OTC-VRPX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Virpax Pharmaceuticals Inc (OTC-VRPX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Virpax Pharmaceuticals Inc (OTC-VRPX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Virpax Pharmaceuticals Inc (OTC-VRPX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Virpax Pharmaceuticals Inc (OTC-VRPX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Virpax Pharmaceuticals Inc (OTC-VRPX) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Virpax Pharmaceuticals Inc (OTC-VRPX) Stock FAQ

Data-supported answers about Virpax Pharmaceuticals Inc (OTC-VRPX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Good
Current financial-health read

A reliable fair value estimate is not currently available for Virpax Pharmaceuticals Inc (OTC-VRPX). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Virpax Pharmaceuticals Inc (OTC-VRPX) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Virpax Pharmaceuticals Inc (OTC-VRPX) is November 13, 2026.

The latest available data indicates no current dividend yield for Virpax Pharmaceuticals Inc (OTC-VRPX).

The current market capitalization listed for Virpax Pharmaceuticals Inc is 0.001 K.

The ticker symbol for Virpax Pharmaceuticals Inc is OTC-VRPX, and the stock is listed on OTC Markets.

Virpax Pharmaceuticals Inc (OTC-VRPX) is listed on OTC Markets.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B